Merck & Co. Inc. (MRK)

I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular por...

Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results...

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.

The past several months have been bullish ones for the market. But not for every stock.

If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but th...

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and anoth...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%.